105-LB: Safety and Performance of an Advanced Hybrid Closed-Loop (AHCL) Algorithm with Ultra-rapid Lispro (URLi) and Lispro von POLLOM, ROBYN K., NOSEK, LESZEK, VEIT COESTER, HANS, ZIJLSTRA, ERIC, GHOSH, ARITRA, HAIDAR, AHMAD, JONES, RICHARD, LEOHR, JENNIFER, GLEISSNER, STEPHANIE E., DASSAU, EYAL, KATZ, MICHELLE

Volltext

Efficacy and safety of ultra‐rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO‐Peds trial von Wadwa, R. Paul, Laffel, Lori M., Franco, Denise R., Dellva, Mary Anne, Knights, Alastair W., Pollom, Robyn K.

Volltext

38-OR: Glycemic Control with Ultrarapid Lispro (URLi) vs. Lispro in Children and Adolescents with T1D: PRONTO-Peds von WADWA, R. PAUL, LAFFEL, LORI M., FRANCO, DENISE R., DELLVA, MARY A., POLLOM, ROBYN K.

Volltext

1018-P: Ultra-Rapid Lispro (URLi) Showed Greater Reduction in Postprandial Glucose (PPG) vs. Humalog in Children, Adolescents, and Adult Patients with Type 1 Diabetes (T1D) von ARONSON, RONNIE, LINNEBJERG, HELLE, LEOHR, JENNIFER, LABELL, ELIZABETH S., COUTANT, DAVID E., ZHANG, QIANYI, DANNE, THOMAS, POLLOM, ROBYN K.

Volltext

Initiating insulin: How to help people with type 2 diabetes start and continue insulin successfully von Polonsky, William H., Arsenault, Joyce, Fisher, Lawrence, Kushner, Pamela, Miller, Eden M., Pearson, Teresa L., Tracz, Mariusz, Harris, Stewart, Hermanns, Norbert, Scholz, Bernd‐M., Pollom, Robyn K., Perez‐Nieves, Magaly, Pollom, Roy Daniel, Hadjiyianni, Irene

Volltext

Lilly Insulin Glargine Versus Lantus® in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5) von Pollom, Robyn K., Ilag, Liza L., Lacaya, Lyndon B., Morwick, Tina M., Ortiz Carrasquillo, Ramón

Volltext

Similar Efficacy and Safety of Basaglar® and Lantus® in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study... von Pollom, Robyn K., Costigan, Timothy, Lacaya, Lyndon B., Ilag, Liza L., Hollander, Priscilla A.

Volltext

Similar Efficacy and Safety of LY2963016 Insulin Glargine and Insulin Glargine (Lantus®) in Patients with T2D in Age Groups (<65, ≥65 Years) von Pollom, Robyn K, Costigan, Tim, Lacaya, Lyndon B, Ilag, Liza L, Hollander, Priscilla

Volltext

Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine von Ilag, Liza L., Costigan, Timothy M., Deeg, Mark A., Pollom, Robyn K., Chang, Curtis L., Konrad, Robert J., Prince, Melvin J.

Volltext

Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2 von Perez-Nieves, Magaly, Pollom, Robyn K, Duan, Ran, Kabul, Samaneh, DeLozier, Amy M, Kaushik, Puneet, Ilag, Liza L

Volltext

Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus Insulin Glargine in Patients with T1DM: The ELEMENT 1 Study von Blevins, Thomas, Dahl, Dominik, Rosenstock, Julio, Huster, William J, Ilag, Liza, Pollom, Robyn K, Prince, Melvin, Lorraine, Joanne

Volltext

Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus Insulin Glargine in Patients with T2DM: The ELEMENT 2 Study von Rosenstock, Julio, Hollander, Priscilla, Bhargava, Anuj, Ilag, Liza, Pollom, Robyn K, Huster, William J, Prince, Melvin, Lorraine, Joanne

Volltext

Evaluation of Immunogenicity of LY2963016 Insulin Glargine Compared with Lantus Insulin Glargine in Patients with T1DM or T2DM von Deeg, Mark A, Ilag, Liza, Huster, William J, Pollom, Robyn K, Zielonka, Jason S, Prince, Melvin, Konrad, Robert J, Lorraine, Joanne

Volltext

Utilization of a multidisciplinary team for inpatient diabetes care von Pollom, Robyn K, Pollom, R Daniel

Volltext

Clinical analytics equal better systemwide outcomes von Pollom, Robyn K, Balbach, Jim, Jones, Kelly A

Volltext

Similar Efficacy and Safety of Basaglar.sup.® and Lantus.sup.® in Patients with Type 2 Diabetes in Age Groups : A Post Hoc Analysis from the ELEMENT-2 Study von Pollom, Robyn K, Costigan, Timothy, Lacaya, Lyndon B, Ilag, Liza L, Hollander, Priscilla A

Volltext

108 - Similar Efficacy and Safety of LY2963016 Insulin Glargine and Insulin Glargine (Lantus®) in Patients with T2D in Age Groups (<65, ≥65 Years) von Pollom, Robyn K., Costigan, Tim, Lacaya, Lyndon B., Ilag, Liza L., Hollander, Priscilla

Volltext

Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus^sup ^ Insulin Glargine von Ilag, Liza L, Costigan, Timothy M, Deeg, Mark A, Pollom, Robyn K, Chang, Curtis L, Konrad, Robert J, Prince, Melvin J

Volltext

CA-095 - Efficacité et tolérance similaires de l’insuline glargine LY2963016 et de l’insuline glargine (Lantus®) chez les patients diabétiques de type 2 dans les groupes d’âge (< 6... von Pollom, Robyn K., Costigan, Tim, Lacaya, Lyndon B., Ilag, Liza L., Hollander, Priscilla

Volltext

Efficacité et tolérance similaires de l’insuline glargine LY2963016 et de l’insuline glargine (Lantus ® ) chez les patients diabétiques de type 2 dans les groupes d’âge (< 65 ans,... von Pollom, Robyn K., Costigan, Tim, Lacaya, Lyndon B., Ilag, Liza L., Hollander, Priscilla

Volltext